Roche: positive CHMP opinion for Ocrevus in MS.
(CercleFinance.com) - Roche announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for the use of its drug Ocrevus in patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis.
If approved, it will provide patients suffering from active recurrent MS with an important therapeutic treatment option, as well as the first and only drug available for patients in the EU with primary progressive MS.
The Swiss health group points out that in Europe, MS affects some 700,000 people, the majority of whom have a form of recurrent MS or a progressive primary MS on diagnosis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
If approved, it will provide patients suffering from active recurrent MS with an important therapeutic treatment option, as well as the first and only drug available for patients in the EU with primary progressive MS.
The Swiss health group points out that in Europe, MS affects some 700,000 people, the majority of whom have a form of recurrent MS or a progressive primary MS on diagnosis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.